These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 32361749

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
    Abbott IJ, Dekker J, van Gorp E, Wijma RA, Raaphorst MN, Klaassen CHW, Meletiadis J, Mouton JW, Peleg AY.
    J Antimicrob Chemother; 2020 Apr 01; 75(4):988-996. PubMed ID: 31873748
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
    Abbott IJ, Meletiadis J, Belghanch I, Wijma RA, Kanioura L, Roberts JA, Peleg AY, Mouton JW.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):709-719. PubMed ID: 29253153
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
    Abbott IJ, Mouton JW, Peleg AY, Meletiadis J.
    J Antimicrob Chemother; 2021 Nov 12; 76(12):3201-3211. PubMed ID: 34473271
    [Abstract] [Full Text] [Related]

  • 6. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome.
    Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY.
    Antimicrob Agents Chemother; 2020 Feb 21; 64(3):. PubMed ID: 31907184
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
    Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Mouton JW, Peleg AY.
    J Microbiol Methods; 2020 Apr 21; 171():105861. PubMed ID: 32035114
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.
    Louie A, Maynard M, Duncanson B, Nole J, Vicchiarelli M, Drusano GL.
    Antimicrob Agents Chemother; 2018 Jun 21; 62(6):. PubMed ID: 29581114
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB.
    Antimicrob Agents Chemother; 2019 Jun 21; 63(6):. PubMed ID: 30910903
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.
    Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB, Landersdorfer CB, Bergen PJ.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1570-1578. PubMed ID: 29506207
    [Abstract] [Full Text] [Related]

  • 14. Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    Abbott IJ, van Gorp E, Cottingham H, Macesic N, Wallis SC, Roberts JA, Meletiadis J, Peleg AY.
    J Antimicrob Chemother; 2023 Feb 01; 78(2):397-410. PubMed ID: 36473954
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.
    Zhanel GG, Parkinson K, Higgins S, Denisuik A, Adam H, Pitout J, Noreddin A, Karlowsky JA.
    Diagn Microbiol Infect Dis; 2017 Jul 01; 88(3):271-275. PubMed ID: 28483306
    [Abstract] [Full Text] [Related]

  • 16. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.
    J Antimicrob Chemother; 2016 Aug 01; 71(8):2218-29. PubMed ID: 27118778
    [Abstract] [Full Text] [Related]

  • 17. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
    Pan AJ, Mei Q, Ye Y, Li HR, Liu B, Li JB.
    J Antibiot (Tokyo); 2017 Feb 01; 70(2):166-173. PubMed ID: 27756910
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
    Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, Kumon H.
    J Infect Chemother; 2007 Oct 01; 13(5):285-90. PubMed ID: 17982715
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
    Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB.
    Antimicrob Agents Chemother; 2017 Aug 01; 61(8):. PubMed ID: 28607025
    [Abstract] [Full Text] [Related]

  • 20. Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Mao J, Li T, Zhang N, Wang S, Li Y, Peng Y, Liu H, Yang G, Yan Y, Jiang L, Liu Y, Li J, Huang X.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0087121. PubMed ID: 34851157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.